NZ590291A - Pharmaceutical compositions for treatment of parkinson's disease - Google Patents

Pharmaceutical compositions for treatment of parkinson's disease

Info

Publication number
NZ590291A
NZ590291A NZ590291A NZ59029109A NZ590291A NZ 590291 A NZ590291 A NZ 590291A NZ 590291 A NZ590291 A NZ 590291A NZ 59029109 A NZ59029109 A NZ 59029109A NZ 590291 A NZ590291 A NZ 590291A
Authority
NZ
New Zealand
Prior art keywords
parkinson
disease
treatment
rasagiline
pramipexole
Prior art date
Application number
NZ590291A
Other languages
English (en)
Inventor
Yoram Sela
Itschak Lamensdorf
Original Assignee
Pharma Two B Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41051156&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NZ590291(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pharma Two B Ltd filed Critical Pharma Two B Ltd
Publication of NZ590291A publication Critical patent/NZ590291A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Toxicology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Biochemistry (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NZ590291A 2008-06-06 2009-06-07 Pharmaceutical compositions for treatment of parkinson's disease NZ590291A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5932608P 2008-06-06 2008-06-06
PCT/IL2009/000567 WO2009147681A1 (en) 2008-06-06 2009-06-07 Pharmaceutical compositions for treatment of parkinson's disease

Publications (1)

Publication Number Publication Date
NZ590291A true NZ590291A (en) 2013-11-29

Family

ID=41051156

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ590291A NZ590291A (en) 2008-06-06 2009-06-07 Pharmaceutical compositions for treatment of parkinson's disease

Country Status (22)

Country Link
US (2) US8969417B2 (enExample)
EP (1) EP2303330B2 (enExample)
JP (1) JP5648216B2 (enExample)
KR (1) KR101613749B1 (enExample)
CN (1) CN102105169B (enExample)
AU (1) AU2009254730B2 (enExample)
BR (1) BRPI0914902B8 (enExample)
CA (1) CA2726833C (enExample)
CL (1) CL2010001358A1 (enExample)
CY (1) CY1119865T1 (enExample)
DK (1) DK2303330T4 (enExample)
ES (1) ES2659394T5 (enExample)
HU (1) HUE037974T2 (enExample)
LT (1) LT2303330T (enExample)
MX (1) MX2010013393A (enExample)
NO (1) NO2303330T3 (enExample)
NZ (1) NZ590291A (enExample)
PL (1) PL2303330T5 (enExample)
PT (1) PT2303330T (enExample)
RU (1) RU2540470C9 (enExample)
WO (1) WO2009147681A1 (enExample)
ZA (1) ZA201100034B (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9943489B2 (en) 2010-02-03 2018-04-17 Pharmatwob Ltd. Extended release formulations of rasagiline and uses thereof
TW201304822A (zh) * 2010-11-15 2013-02-01 Vectura Ltd 組成物及用途
US9504657B2 (en) * 2012-01-12 2016-11-29 Pharmatwob Ltd. Fixed dose combination therapy of Parkinson's disease
JP6243351B2 (ja) * 2012-01-12 2017-12-06 ファーマ ツゥ ビー リミテッド パーキンソン病の固定投与量薬剤組合せ治療
WO2013168032A1 (en) * 2012-05-07 2013-11-14 Micro Labs Limited Pharmaceutical compositions comprising rasagiline
KR101320945B1 (ko) * 2012-07-03 2013-10-23 주식회사파마킹 에스-알릴-엘-시스테인을 유효성분으로 포함하는 대장염 예방 또는 치료용 조성물 및 이를 포함하는 의약제제
MX2015003812A (es) * 2012-09-27 2015-07-17 Teva Pharma Combinacion de rasagilina y pridopidina para tratar trastornos neurodegenerativos, en particular enfermedad de huntington.
BR112015022896B1 (pt) 2013-03-15 2022-08-23 Chongxi Yu Composto de fármacos de alta penetração, composição farmacêutica e seus usos para o tratamento de doenças de parkinson
EP2808023A1 (en) * 2013-05-30 2014-12-03 Université Pierre et Marie Curie (Paris 6) New drug for the treatment and/or prevention of depressive disorders
CN104473942A (zh) * 2014-12-12 2015-04-01 青岛大学 一种抗帕金森氏病的药物组合物
CA2986891C (en) 2015-05-26 2022-01-04 Technophage, Investigacao E Desenvolvimento Em Biotecnologia, Sa Compositions for use in treating parkinson's disease and related disorders
WO2017070293A1 (en) * 2015-10-20 2017-04-27 Ironwood Pharmaceuticals, Inc. Phosphodiesterase 9 inhibitor and levodopa therapy
US20170143681A1 (en) * 2015-11-02 2017-05-25 Apkarian Technologies Llc Methods and compositions for treating pain
EP3558378A4 (en) * 2016-12-22 2020-09-16 Synnerva Ltd. LOW DOSE COMBINATION OF MEDICINAL PRODUCTS FOR THE PREVENTION AND TREATMENT OF NEURAL DAMAGE
WO2019010491A1 (en) * 2017-07-07 2019-01-10 University Of Pittsburgh-Of The Commonwealth System Of Higher Education COMBINATIONS OF MEDICINES FOR THE PROTECTION AGAINST THE DEATH OF NEURONAL CELLS
US20190153102A1 (en) 2017-09-28 2019-05-23 Prothena Biosciences Limited Dosing regimes for treatment of synucleinopathies
JP6596483B2 (ja) * 2017-12-28 2019-10-23 テックフィールズ ファーマ カンパニー リミテッド パ−キンソン病治療用の新規高透過薬物及びその組成物
WO2020084168A1 (en) * 2018-10-26 2020-04-30 Icm (Institut Du Cerveau Et De La Moelle Épinière) Tetracycline compound for treating drug-induced dyskinesia
CN113924086A (zh) * 2019-04-17 2022-01-11 维奇健康科学有限责任公司 液体药物组合物
WO2020227646A1 (en) * 2019-05-09 2020-11-12 Apkarian Technologies Llc Methods and compositions for treating pain
US20230028539A1 (en) 2019-12-06 2023-01-26 Shanghai Pharmaceuticals Holding Co., Ltd. Pharmaceutical composition, complementary kit and application thereof
AU2021292406B2 (en) 2020-06-18 2024-03-14 XWPharma Ltd. Controlled release granulations of water-soluble active pharmaceutical ingredients
WO2022020621A1 (en) 2020-07-24 2022-01-27 XWPharma Ltd. Pharmaceutical compositions and pharmacokinetics of a gamma-hydroxybutyric acid derivative
TW202227131A (zh) * 2020-09-10 2022-07-16 愛爾蘭商普羅佘納生物科技有限公司 帕金森氏症之治療
AU2021357705B2 (en) 2020-10-05 2024-09-26 XWPharma Ltd. Modified release compositions of a gamma-hydroxybutyric acid derivative
CN114762684B (zh) * 2021-01-14 2023-11-21 华益泰康药业股份有限公司 一种治疗帕金森的缓释胶囊及其制备方法
DK4308086T3 (da) 2021-03-19 2025-11-17 Xwpharma Ltd Farmakokinetik af formuleringer med kombineret frigivelse af et gamma-hydroxysmørsyrederivat
KR102903389B1 (ko) * 2022-11-30 2025-12-23 주식회사한국파마 신경퇴행성 질환 예방 또는 치료용 필름코팅정제

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0241809B1 (de) * 1986-04-16 1990-08-08 ASTA Pharma Aktiengesellschaft Synergistische Kombination von Amantadin und Selegilin
US5221536A (en) * 1990-05-07 1993-06-22 Alza Corporation Dosage form indicated for the management of abnormal posture, tremor and involuntary movement
US5190763A (en) 1990-05-07 1993-03-02 Alza Corporation Dosage form indicated for the management of abnormal posture, tremor and involuntary movement
DK0828513T3 (da) * 1995-05-26 2004-04-13 Pfizer Kombinationspræparater til behandling af parkinsonisme, indeholdende selektive NMDA-antagonister
CN1436080A (zh) 2000-04-19 2003-08-13 利利艾科斯有限公司 环gmp－特异性磷酸二酯酶抑制剂治疗帕金森氏病的用途
US20070225379A1 (en) * 2001-08-03 2007-09-27 Carrara Dario Norberto R Transdermal delivery of systemically active central nervous system drugs
AR044007A1 (es) * 2003-04-11 2005-08-24 Newron Pharmaceuticals Inc Metodos para el tratamiento de la enfermedad de parkinson
FR2857594B1 (fr) * 2003-07-17 2005-09-16 Servier Lab Composition pharmaceutique pour l'administration par voie nasale de piribedil
KR20060124712A (ko) 2004-02-20 2006-12-05 노파르티스 아게 신경퇴행 및 인지 장애를 치료하기 위한 ｄｐｐ ⅳ 억제제
EP1901721A1 (en) 2005-06-23 2008-03-26 Spherics, Inc. Delayed release or extended-delayed release dosage forms of pramipexole
US20090325911A1 (en) 2005-10-21 2009-12-31 Caritas St. Elizabeth Medical Center Of Boston, Inc. Use of Androgens for the Treatment of Parkinson's Disease
EP1970055B1 (en) * 2005-12-29 2010-11-24 Osmotica Kereskedelmi És Szolgáltató Kft Multi-layered tablet with triple release combination
BRPI0708071A8 (pt) 2006-02-17 2017-12-26 Birds Pharma Gmbh Berolina Innovative Res & Development Services Derivados de catecolamina deuterada e medicamentos compreendendo os ditos compostos
AU2007235517B2 (en) 2006-04-03 2013-01-31 Teva Pharmaceutical Industries, Ltd. Use of rasagiline for the treatment of Restless Legs Syndrome
CN102160865A (zh) * 2006-05-16 2011-08-24 诺普神经科学股份有限公司 R(+)和s(-)普拉克索的组合物以及使用该组合物的方法
EP2040698A4 (en) 2006-07-14 2011-08-10 Shionogi & Co OXIM CONNECTIONS AND ITS USE
TW200820963A (en) 2006-07-28 2008-05-16 Xenoport Inc Acyloxyalkyl carbamate prodrugs of α-amino acids, methods of synthesis and use
ATE510538T1 (de) 2006-08-11 2011-06-15 Univ Johns Hopkins Zusammensetzungen und verfahren für nervenschutz
CN101573334A (zh) 2006-08-21 2009-11-04 普雷萨药品公司 用于治疗中枢神经系统障碍的多介质转运体抑制剂
US7622495B2 (en) 2006-10-03 2009-11-24 Neurim Pharmaceuticals (1991) Ltd. Substituted aryl-indole compounds and their kynurenine/kynuramine-like metabolites as therapeutic agents
ES2389456T3 (es) 2006-11-01 2012-10-26 Purdue Pharma Lp Compuestos de fenilpropionamida y uso de los mismos
EP2150239A1 (en) † 2007-04-24 2010-02-10 Boehringer Ingelheim International GmbH Combination with an extended release tablet formulation containing pramipexole or a pharmaceutically acceptable salt thereof

Also Published As

Publication number Publication date
KR20110031181A (ko) 2011-03-24
RU2540470C9 (ru) 2015-07-20
EP2303330A1 (en) 2011-04-06
CA2726833A1 (en) 2009-12-10
JP5648216B2 (ja) 2015-01-07
DK2303330T4 (da) 2021-09-13
ES2659394T3 (es) 2018-03-15
RU2540470C2 (ru) 2015-02-10
US20150133513A1 (en) 2015-05-14
ZA201100034B (en) 2012-04-25
HUE037974T2 (hu) 2018-09-28
EP2303330B1 (en) 2017-11-15
BRPI0914902B8 (pt) 2022-04-12
WO2009147681A1 (en) 2009-12-10
EP2303330B2 (en) 2021-06-16
CN102105169A (zh) 2011-06-22
CA2726833C (en) 2016-03-22
MX2010013393A (es) 2011-06-21
BRPI0914902A2 (pt) 2017-06-20
US8969417B2 (en) 2015-03-03
KR101613749B1 (ko) 2016-04-19
AU2009254730B2 (en) 2014-06-26
JP2011522035A (ja) 2011-07-28
LT2303330T (lt) 2018-04-10
PT2303330T (pt) 2018-02-12
CL2010001358A1 (es) 2011-08-19
RU2010154716A (ru) 2012-08-10
CN102105169B (zh) 2014-09-10
US20110230513A1 (en) 2011-09-22
BRPI0914902B1 (pt) 2022-02-22
AU2009254730A1 (en) 2009-12-10
PL2303330T3 (pl) 2018-04-30
ES2659394T5 (es) 2021-12-13
NO2303330T3 (enExample) 2018-04-14
CY1119865T1 (el) 2018-06-27
DK2303330T3 (en) 2018-02-26
PL2303330T5 (pl) 2021-10-25
US9259418B2 (en) 2016-02-16

Similar Documents

Publication Publication Date Title
EA201270221A1 (ru) Лечение болезни крона с применением лаквинимода
NZ589445A (en) Rasagiline for parkinson's disease modification
HK1221646A1 (zh) 高剂量普利多匹定用於治疗亨廷顿舞蹈症的用途
CR11724A (es) Agente para tratar enfermedades
NZ605887A (en) Pharmaceutical dosage form comprising 6’-fluoro-(n-methyl- or n,n-dimethyl-)-4-phenyl-4’,9’-dihydro-3’h-spiro[cyclohexane-1,1’-pyrano[3,4,b]indol]-4-amine for the treatment of neuropathic pain
JP2010522242A5 (enExample)
MX2009003372A (es) Formas de dosificacion de pelicula no mucoadhesiva.
JP2015524444A5 (enExample)
FI3504187T3 (fi) Pridopidiinin käyttö toiminnallisen heikkenemisen hoitoa varten
WO2012079092A3 (en) Testosterone undecanoate compositions
UA110012C2 (uk) Лікарські форми для перорального застосування, що містять ацетат лікарбазепіну
PH12013500406A1 (en) Deuterated analogs of pridopidine useful as dopaminergic stabilizers
MX354423B (es) Formulaciones de rasagilina de liberación prolongada y usos de las mismas.
WO2008084504A3 (en) Pharmaceutical compositions of angiotensin ii receptor blockers
AR075735A1 (es) Composiciones farmaceuticas de liberacion inmediata que comprenden oxicodona y naloxona. uso
JP2009537554A5 (enExample)
RU2020107732A (ru) Схема дозирования модулятора s1p с немедленным высвобождением
BRPI0914902B8 (pt) Composição farmacêutica para uso no tratamento de mal de parkinson
MY168531A (en) Medicament form for release of active ingredients
NZ560669A (en) Use of alkyl cellulose as controlled release matrix material in alcohol resistant dosage forms
JP2018039810A5 (enExample)
PH12013500552A1 (en) Enhanced transbuccal drug delivery system and compositions
MX341660B (es) Agonista del receptor de ghrelina para el tratamiento de caquexia.
BRPI0513598A (pt) formas de dosagem em comprimidos revestidos de liberação entérica
CN104706604A (zh) 一种吡仑帕奈冻干口崩片及其制备方法

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 07 JUN 2016 BY SHELSTON IP

Effective date: 20140305

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 07 JUN 2017 BY DENNEMEYER + CO.

Effective date: 20160603

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 07 JUN 2018 BY DENNEMEYER + CO

Effective date: 20170601

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 07 JUN 2019 BY DENNEMEYER + CO

Effective date: 20180526

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 07 JUN 2020 BY DENNEMEYER + CO.

Effective date: 20190522

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 07 JUN 2021 BY PETRA OLK

Effective date: 20200604

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 07 JUN 2022 BY DENNEMEYER + CO.

Effective date: 20210604

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 07 JUN 2023 BY DENNEMEYER + CO.

Effective date: 20220530

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 07 JUN 2024 BY DENNEMEYER + CO. S.A R.L.

Effective date: 20230531

LAPS Patent lapsed